Claims
- 1. A molecular switch protein for regulating expression from a promoter transcriptionally linked to a nucleic acid encoding a desired gene product, said molecular switch protein comprising:
a DNA binding domain which binds the promoter; a transregulatory domain which regulates transcription from the promoter when the molecular switch protein is bound to an agonist for said molecular switch protein and to the promoter; and a mutated steroid hormone receptor superfamily protein ligand binding domain comprising a deletion of about five to about 42 carboxy terminal amino acids from a naturally occurring steroid hormone receptor superfamily protein ligand binding domain, wherein the mutation confers efficient activation of the molecular switch protein by the agonist which is an antagonist of the naturally occurring steroid hormone receptor superfamily protein.
- 2. The molecular switch protein of claim 1, wherein the transregulatory domain is a transactivation domain that is different from a transactivation domain that is naturally associated with the mutated steroid hormone receptor superfamily protein ligand binding domain.
- 3. The molecular switch protein of claim 2, wherein the transactivation domain is selected from the group consisting of VP-16, TAF-1, TAF-2, TAU-1 and TAU-2.
- 4. The molecular switch protein of claim 1, wherein the DNA binding domain is selected from the group consisting of glucocorticoid receptor DNA binding domain, progesterone receptor DNA binding domain and GAL-4 DNA binding domain.
- 5. The molecular switch protein of claim 1, wherein the DNA binding domain is selected from the group consisting of yeast DNA binding domain, a virus DNA binding domain, an insect DNA binding domain, or a non-mammalian DNA binding domain.
- 6. The molecular switch protein of claim 5, wherein the yeast DNA binding domain is a GAL-4 DNA binding domain.
- 7. The molecular switch protein of claim 1, wherein the transregulatory domain is a VP-16 transactivation domain and the DNA binding domain is GAL-4 DNA binding domain.
- 8. The molecular switch protein of claim 1, wherein said mutated steroid hormone receptor superfamily protein ligand binding domain is selected from the group consisting of estrogen, progesterone, glucocorticoid-α, glucocorticoid-β, mineralocorticoid, androgen, thyroid hormone, retinoic acid, retinoid X, Vitamin D, COUP-TF, ecdysone, Nurr-1 and orphan receptors.
- 9. The molecular switch protein of claim 8, wherein the mutated steroid hormone receptor superfamily protein ligand binding domain is a mutated progesterone receptor protein ligand binding domain.
- 10. The molecular switch protein of claim 9, wherein the carboxy terminal deletion comprises a deletion of about 16 to about 19 amino acids.
- 11. The molecular switch protein of claim 1, wherein the mutated steroid hormone receptor superfamily protein ligand binding domain binds a non-natural ligand.
- 12. The molecular switch protein of claim 11, wherein the mutated steroid hormone receptor superfamily protein ligand binding domain binds a non-natural ligand selected from the group consisting of 5-alpha-pregnane-3,20-dione; 11β-(4-dimethylaminophenyl)-17β-hydroxy-17α-propinyl-4,9-estradiene-3-one; 11β-(4-dimethylaminophenyl)-17α-hydroxy-17β-(3-hydroxypropyl)-13α-methyl-4,9-gonadiene-3-one; 11β-(4-acetylphenyl)-17β-hydroxy-17α-(1-propinyl)-4,9-estradiene-3-one; 11β-(4-dimethylaminophenyl)-17β-hydroxy-17α-(3-hydroxy-1(Z)-propenyl-estra-4,9-diene-3 one; (7β,11β,17β)-11-(4-dimethylaminophenyl)-7-methyl-4′,5′-dihydrospiro(ester 4,9-diene 17,2′(3′H)-furan)-3-one; (11β,14β,17α)-4′,5′-dihydro-11-(4-dimethylaminophenyl)-(spiroestra-4,9-diene-17,2′(3′H)-furan)-3-one.
- 13. The molecular switch protein of claim 1 or claim 9, wherein the mutated steroid hormone receptor superfamily protein ligand binding domain binds an antiprogestin.
- 14. The molecular switch protein of claim 13, wherein the antiprogestin is selected from the group consisting of Org31806, Org31376, and RU486.
- 15. The molecular switch protein of claim 14, wherein the antiprogestin is RU486.
- 16. A molecular switch protein for regulating expression from a promoter transcriptionally linked to a nucleic acid encoding a desired gene product, said molecular switch protein comprising:
a GAL-4 DNA binding domain which binds the promoter; a transactivation domain which regulates transcription from the promoter when the molecular switch protein is bound to an agonist for the molecular switch protein and to the promoter; and a mutated progesterone receptor protein ligand binding domain comprising a deletion of about 16 to about 42 carboxy terminal amino acids from a naturally occurring progesterone receptor protein ligand binding domain, wherein the mutation confers efficient activation of the molecular switch protein by the agonist which is an antagonist of the naturally occurring progesterone receptor protein.
- 17. The molecular switch protein of claim 16, wherein the mutated progesterone receptor protein ligand binding domain binds to, and is efficiently activated by, an antiprogestin.
- 18. The molecular switch protein of claim 17, wherein the antiprogestin is selected from the group consisting of Org31806, Org31376, and RU486.
- 19. The molecular switch protein of claim 18, wherein the antiprogestin is RU486.
- 20. A nucleic acid expression system comprising:
a first nucleic acid cassette having a first nucleic acid sequence encoding for a fusion protein; wherein the fusion protein comprises: a DNA-binding domain; a transregulatory domain; and a mutated steroid hormone receptor superfamily protein ligand binding domain comprising a deletion of about 5 to about 54 carboxy terminal amino acids from a naturally occurring steroid hormone superfamily receptor protein ligand binding domain; and a second expression cassette having a second nucleic acid sequence comprising a promoter operably linked to a nucleic acid sequence encoding a gene product, wherein the expression of the gene product is activated by binding of the fusion protein to the promoter.
- 21. The fusion protein of claim 20, wherein the transregulatory domain is a transactivation domain
- 22. The fusion protein of claim 21, wherein the transactivation domain is selected from the group consisting of VP-16, TAF-1, TA-2, TAU-1 and TAU-2.
- 23. The fusion protein of claim 20, wherein the DNA binding domain is selected from the group consisting of glucocorticoid receptor DNA binding domain, progesterone receptor DNA binding domain and GAL-4 DNA binding domain.
- 24. The fusion protein of claim 20, wherein the DNA binding domain is selected from the group consisting of a yeast DNA binding domain, a virus DNA binding domain, an insect DNA binding domain, or a non-mammalian DNA binding domain.
- 25. The fusion protein of claim 24, wherein the yeast DNA binding domain is a GAL-4 DNA binding domain.
- 26. The fusion protein of claim 20, wherein the transregulatory domain is a transactivation domain that is different from a transactivation domain that is naturally associated with the mutated steroid hormone receptor superfamily protein ligand binding domain and the DNA binding domain is GAL-4 DNA binding domain.
- 27. The fusion protein of claim 20, wherein said mutated steroid hormone receptor superfamily protein ligand binding domain is selected from the group consisting of estrogen, progesterone, glucocorticoid-α, glucocorticoid-β, mineralo-corticoid, androgen, thyroid hormone, retinoic acid, retinoid X, Vitamin D, COUP-TF, ecdysone, Nurr-1 and orphan receptors.
- 28. The fusion protein of claim 20, wherein the mutated steroid hormone receptor superfamily protein ligand binding domain binds a non-natural ligand.
- 29. The fusion protein of claim 28, wherein the mutated steroid hormone receptor superfamily protein ligand binding domain binds a non-natural ligand selected from the group consisting of 5-alpha-pregnane-3,20-dione; 11β-(4-dimethylaminophenyl)-17β-hydroxy-17α-propinyl-4,9-estradiene-3-one; 11β-(4-dimethylaminophenyl)-17α-hydroxy-17β-(3-hydroxypropyl)-13α-methyl-4,9-gonadiene-3-one; 11β-(4-acetylphenyl)-17β-hydroxy-17α-(1-propinyl)-4,9-estradiene-3-one; 11β-(4-dimethylaminophenyl)-17β-hydroxy-17α-(3-hydroxy-1(Z)-propenyl-estra-4,9-diene-3 one; (7β,11β,17β)-11-(4-dimethylaminophenyl)-7-methyl-4′,5′-dihydrospiro(ester-4,9-diene 17,2′(3′H)-furan)-3-one; (11β,14β,17α)-4′,5′-dihydro-11-(4-dimethylaminophenyl)-(spiroestra-4,9-diene-17,2′(3′H)-furan)-3-one.
- 30. The fusion protein of claim 27, wherein the mutated steroid hormone receptor superfamily protein ligand binding domain is a mutated progesterone receptor protein ligand binding domain.
- 31. The fusion protein of claim 30, wherein the mutated progesterone receptor superfamily protein ligand binding domain binds to, and is efficiently activated by, an antiprogestin.
- 32. The fusion protein of claim 31, wherein the antiprogestin is selected from the group consisting of Org31806, Org31376, and RU486.
- 33. The fusion protein of claim 32, wherein the antiprogestin is RU486.
- 34. A polynucleotide encoding a regulator protein capable of regulating transcription, the regulator protein comprising:
a DNA binding domain; a transregulatory domain; and a mutated progesterone receptor ligand binding domain having a carboxy terminal amino acid truncation of about 5 to about 54 amino acids, wherein the truncated ligand binding domain binds an anti-progestin and said binding activates the regulator protein to control transcription of an RNA encoding a desired gene product.
- 35. The polynucleotide encoding an inducible transcription regulator protein of claim 34, wherein the anti-progestin is RU486.
- 36. The polynucleotide encoding the inducible transcription regulator protein of claim 35, wherein the mutated progesterone receptor ligand binding domain has a carboxy terminal amino acid truncation of about 5 to about 42 amino acids.
- 37. The polynucleotide encoding the inducible transcription regulator protein of claim 36, wherein the mutated progesterone receptor ligand binding domain has a carboxy terminal amino acid truncation of about 16 to about 19 amino acids and wherein the truncation confers about a 10 fold increased sensitivity to RU486 over that of a carboxy terminal amino acid truncation of about 42 amino acids.
- 38. The polynucleotide encoding the inducible transcription regulator protein of claim 34, wherein the transregulatory domain is a transactivation domain.
- 39. A method for regulating expression of a desired gene product, comprising the steps of:
introducing into an animal cell a first nucleic acid cassette encoding a desired protein under the transcriptional control of a molecular switch promoter, and a second nucleic acid cassette encoding a molecular switch protein, wherein the molecular switch protein comprises: a DNA binding domain which binds the molecular switch promoter; a mutated steroid hormone receptor superfamily ligand binding domain which does not bind a natural ligand and binds a non-natural ligand for the steroid hormone receptor superfamily ligand binding domain, and a transregulatory domain that regulates transcription from the molecular switch promoter when the molecular switch protein is bound to the molecular switch promoter and to said non-natural ligand, wherein transcription of an RNA encoding the desired gene product is regulated by administering the non-natural ligand to the cell.
- 40. The method for regulating expression of the desired gene product of claim 39, wherein the first and second nucleic acid cassettes are introduced into the cell in vitro to form a transformed cell; and the transformed cell is introduced into an animal.
- 41. The method for regulating expression of the desired gene product of claim 40, wherein transregulation of expression of the gene product is controlled by administering the non-natural ligand to the animal in vivo.
- 42. The method of regulating expression of a desired gene product of claim 41, wherein the animal is a transgenic animal.
- 43. The method of claim 39, wherein the mutated steroid hormone superfamily receptor ligand binding domain is selected from the group consisting of estrogen, androgen, Vitamin D, COUP-TF, cis-retinoic acid, Nurr-1, thyroid hormone, mineralocorticoid, glucocorticoid-α, glucocorticoid-β, and orphan receptors.
- 44. The method of claim 39, wherein the molecular switch protein comprises a mutated progesterone receptor ligand binding domain together with a non-progesterone DNA binding and transactivation domains.
- 45. The method of claim 39, wherein the first and second nucleic acid cassettes are introduced into an animal cell in vivo.
- 46. The method of claim 45, wherein the animal is administered a non-natural ligand which activates the molecular switch protein to control transcription of the RNA encoding the desired gene product.
- 47. The method of claims 40 and 45, wherein the first and second nucleic acid cassettes are contained in separate vectors.
- 48. The method of claim 39, wherein the molecular switch protein comprises a non-native or modified DNA binding domain.
- 49. The method of claim 39, wherein the amount of gene product produced by the cell is proportional to the dose of the non-natural ligand administered.
Priority Claims (1)
| Number |
Date |
Country |
Kind |
| PCT/US97/19607 |
Oct 1997 |
WO |
|
CLAIM OF PRIORITY
[0001] The present application is a continuation of co-pending U.S. patent application Ser. No. 09/916,145, filed Jul. 25, 2001 entitled MODIFIED HORMONES FOR GENE THERAPY AND METHODS OF THEIR USE by O'Malley et al. (Lyon & Lyon Docket No. 264/035), which is a continuation of U.S. patent application Ser. No. 08/959,013, filed Oct. 28, 1997, now abandoned, entitled “MODIFIED STEROID HORMONES FOR GENE THERAPY AND METHODS OF THEIR USE” by O'Malley et al. (Lyon & Lyon Docket No. 226/286), which claims priority to U.S. Provisional Patent Application Serial No. 60/029,964, filed Oct. 29, 1996, entitled “MODIFIED STEROID HORMONES FOR GENE THERAPY AND METHODS OF THEIR USE” by O'Malley et al. (Lyon & Lyon Docket No. 222/085);
[0002] The present application is a continuation-in-part of co-pending U.S. application Ser. No. 08/479, 913 (Lyon & Lyon Docket No. 212/133), O'Malley et al., filed Jun. 7,1995, entitled “MODIFIED STEROID HORMONES FOR GENE THERAPY AND METHODS OF THEIR USE.”
[0003] The present application is a continuation-in-part of co-pending U.S. application Ser. No. 09/465,133 (Lyon & Lyon Docket No. 246/180), Vegeto et al., filed Dec. 16, 1999, entitled “MUTATED STEROID HORMONE RECEPTORS, METHODS FOR THEIR USE AND MOLECULAR SWITCH FOR GENE THERAPY,” which is a continuation application of U.S. application Ser. No. 09/209,981 (Lyon & Lyon Docket No. 237/177), Vegeto et al., filed Dec. 9, 1998, entitled “MUTATED STEROID HORMONE RECEPTORS, METHODS FOR THEIR USE AND MOLECULAR SWITCH FOR GENE THERAPY,” which is a divisional application of U.S. application Ser. No. 08/479,846, filed Jun. 6, 1995, now U.S. Pat. No. 5,874,534, Vegeto et al, issued Feb. 23, 1999, entitled “MUTATED STEROID HORMONE RECEPTORS, METHODS FOR THEIR USE AND MOLECULAR SWITCH FOR GENE THERAPY,” which is a continuation of U.S. application Ser. No. 07/939,246, Vegeto et al., filed Sep. 2, 1992, entitled “MUTATED STEROID HORMONE RECEPTORS, METHODS FOR THEIR USE AND MOLECULAR SWITCH FOR GENE THERAPY,” now abandoned, which is a continuation-in-part of U.S. application Ser. No. 07/882,771, filed May 14, 1992, now U.S. Pat. No. 5,364,791, entitled “PROGESTERONE RECEPTOR HAVING C TERMINAL HORMONE BINDING DOMAIN TRUNCATIONS.”
Government Interests
[0004] The invention described herein was developed in part with funds provided by the National Institutes of Health, Grant Number HD07857. The Government has certain rights.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60029964 |
Oct 1996 |
US |
Divisions (1)
|
Number |
Date |
Country |
| Parent |
08479846 |
Jun 1995 |
US |
| Child |
09209981 |
Dec 1998 |
US |
Continuations (4)
|
Number |
Date |
Country |
| Parent |
09916145 |
Jul 2001 |
US |
| Child |
10124741 |
Apr 2002 |
US |
| Parent |
08959013 |
Oct 1997 |
US |
| Child |
09916145 |
Jul 2001 |
US |
| Parent |
09209981 |
Dec 1998 |
US |
| Child |
09465133 |
Dec 1999 |
US |
| Parent |
07939246 |
Sep 1992 |
US |
| Child |
08479846 |
Jun 1995 |
US |
Continuation in Parts (3)
|
Number |
Date |
Country |
| Parent |
08479913 |
Jun 1995 |
US |
| Child |
10124741 |
Apr 2002 |
US |
| Parent |
09465133 |
Dec 1999 |
US |
| Child |
10124741 |
Apr 2002 |
US |
| Parent |
07882771 |
May 1992 |
US |
| Child |
07939246 |
Sep 1992 |
US |
Patent Application
20030109683
